|
|
Volumn 300, Issue 13, 2008, Pages 1503-1505
|
|
Risks and benefits of direct-to-consumer genetic testing remain unclear
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BRCA1 PROTEIN;
FIBROBLAST GROWTH FACTOR RECEPTOR 2;
BREAST CANCER;
CANCER RISK;
CONSUMER;
GENE MUTATION;
GENETIC ANALYSIS;
GENETIC MARKER;
GENETIC PROCEDURES;
GENETIC RISK;
GENETIC VARIABILITY;
HEALTH HAZARD;
HIGH THROUGHPUT SCREENING;
HUMAN;
MEDICAL INFORMATION;
MEDICAL SOCIETY;
MICROARRAY ANALYSIS;
OVARY CANCER;
PRIORITY JOURNAL;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
RISK REDUCTION;
SHORT SURVEY;
SINGLE NUCLEOTIDE POLYMORPHISM;
CONSUMER HEALTH INFORMATION;
ETHICS;
GENETIC SCREENING;
GOVERNMENT;
LEGAL ASPECT;
NOTE;
PSYCHOLOGICAL ASPECT;
UNITED STATES;
CONSUMER HEALTH INFORMATION;
GENETIC MARKERS;
GENETIC SCREENING;
HUMANS;
STATE GOVERNMENT;
UNITED STATES;
|
|
EID: 54849159800
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.300.13.1503 Document Type: Short Survey |
|
Times cited : (26)
|
|
References (0)
|